AU765336B2 - Optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases - Google Patents

Optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases Download PDF

Info

Publication number
AU765336B2
AU765336B2 AU17906/00A AU1790600A AU765336B2 AU 765336 B2 AU765336 B2 AU 765336B2 AU 17906/00 A AU17906/00 A AU 17906/00A AU 1790600 A AU1790600 A AU 1790600A AU 765336 B2 AU765336 B2 AU 765336B2
Authority
AU
Australia
Prior art keywords
oxadiazine
pyridyl
methyl
piperidinyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU17906/00A
Other languages
English (en)
Other versions
AU1790600A (en
Inventor
Karoly Acsai
Erno Bacsy
Mihaly Barabas
Zita Csakai
Laszlo Denes
Andrea Jednakovits
Zsuzsanna Korom
Peter Krajcsi
Istvan Kurucz
Ede Marvanyos
Zoltan Nagy
Jeno Szilbereky
Magdolna Torok
Laszlo Urge
Laszlo Urogdi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Strategic Partners AS
Original Assignee
Biorex Kutato Fejleszto Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Fejleszto Kft filed Critical Biorex Kutato Fejleszto Kft
Publication of AU1790600A publication Critical patent/AU1790600A/en
Application granted granted Critical
Publication of AU765336B2 publication Critical patent/AU765336B2/en
Assigned to CYTRX CORPORATION reassignment CYTRX CORPORATION Alteration of Name(s) in Register under S187 Assignors: BIOREX KUTATO ES FEJLESZTO RT.
Assigned to ORPHAZYME APS reassignment ORPHAZYME APS Alteration of Name(s) in Register under S187 Assignors: CYTRX CORPORATION
Assigned to ORPHAZYME A/S reassignment ORPHAZYME A/S Request to Amend Deed and Register Assignors: ORPHAZYME APS
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU17906/00A 1998-12-14 1999-12-07 Optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases Expired AU765336B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU9802897A HU226617B1 (en) 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
HU9802897 1998-12-14
PCT/HU1999/000095 WO2000035914A1 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases

Publications (2)

Publication Number Publication Date
AU1790600A AU1790600A (en) 2000-07-03
AU765336B2 true AU765336B2 (en) 2003-09-18

Family

ID=10991166

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17906/00A Expired AU765336B2 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases

Country Status (27)

Country Link
US (1) US6384029B1 (cg-RX-API-DMAC7.html)
EP (1) EP1147105B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002532498A (cg-RX-API-DMAC7.html)
KR (1) KR100661774B1 (cg-RX-API-DMAC7.html)
AT (1) ATE266027T1 (cg-RX-API-DMAC7.html)
AU (1) AU765336B2 (cg-RX-API-DMAC7.html)
BG (1) BG65179B1 (cg-RX-API-DMAC7.html)
BR (1) BR9913982A (cg-RX-API-DMAC7.html)
CA (1) CA2340734C (cg-RX-API-DMAC7.html)
CZ (1) CZ300764B6 (cg-RX-API-DMAC7.html)
DE (1) DE69917074T2 (cg-RX-API-DMAC7.html)
DK (1) DK1147105T3 (cg-RX-API-DMAC7.html)
EE (1) EE04551B1 (cg-RX-API-DMAC7.html)
ES (1) ES2219091T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20010133B1 (cg-RX-API-DMAC7.html)
HU (1) HU226617B1 (cg-RX-API-DMAC7.html)
IL (1) IL141515A (cg-RX-API-DMAC7.html)
NO (1) NO317649B1 (cg-RX-API-DMAC7.html)
PL (1) PL196584B1 (cg-RX-API-DMAC7.html)
PT (1) PT1147105E (cg-RX-API-DMAC7.html)
RS (1) RS50129B (cg-RX-API-DMAC7.html)
RU (1) RU2222538C2 (cg-RX-API-DMAC7.html)
SI (1) SI1147105T1 (cg-RX-API-DMAC7.html)
SK (1) SK285582B6 (cg-RX-API-DMAC7.html)
UA (1) UA70340C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000035914A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200101182B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057664A1 (en) 2002-01-11 2003-07-17 Biorex Kutató És Fejlesztö Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
KR100678577B1 (ko) * 2006-09-11 2007-02-06 조만규 가정용 분전함
JP5616336B2 (ja) 2008-06-26 2014-10-29 オルファザイム エーピーエスOrphazyme Aps 酵素活性の調節因子としてのHsp70の使用
KR20110084514A (ko) 2008-11-18 2011-07-25 산텐 세이야꾸 가부시키가이샤 피리딘-3-카르발데히드 o-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
WO2018215597A1 (en) 2017-05-24 2018-11-29 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
MX2020012480A (es) 2018-05-28 2021-03-25 Orphazyme As Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3704997A (en) * 1996-08-09 1998-03-06 Cytrx Corporation Pharmaceutical products for curing and preventing diseases resulting from the damaging of the vascular endothelial cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395853B (de) * 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
DE69628320D1 (de) * 1995-11-03 2003-06-26 Summit Packaging Systems Ltd Vorrichtung zum abgeben und füllen von beuteln an einem kassenplatz eines supermarkts

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3704997A (en) * 1996-08-09 1998-03-06 Cytrx Corporation Pharmaceutical products for curing and preventing diseases resulting from the damaging of the vascular endothelial cells

Also Published As

Publication number Publication date
IL141515A0 (en) 2002-03-10
RS50129B (sr) 2009-03-25
EE200100188A (et) 2002-08-15
DE69917074T2 (de) 2005-05-12
DE69917074D1 (de) 2004-06-09
SK2342001A3 (en) 2001-08-06
WO2000035914A1 (en) 2000-06-22
PL196584B1 (pl) 2008-01-31
US6384029B1 (en) 2002-05-07
BG105342A (en) 2001-12-29
EE04551B1 (et) 2005-10-17
ES2219091T3 (es) 2004-11-16
HRP20010133B1 (en) 2005-02-28
CZ300764B6 (cs) 2009-08-05
HU9802897D0 (en) 1999-02-01
HUP9802897A3 (en) 2001-08-28
CA2340734C (en) 2008-10-21
BR9913982A (pt) 2001-06-12
JP2011201916A (ja) 2011-10-13
YU25001A (sh) 2004-07-15
HU226617B1 (en) 2009-04-28
PT1147105E (pt) 2004-07-30
KR100661774B1 (ko) 2006-12-28
ZA200101182B (en) 2002-02-12
RU2222538C2 (ru) 2004-01-27
SI1147105T1 (en) 2004-08-31
JP5620340B2 (ja) 2014-11-05
JP2002532498A (ja) 2002-10-02
HRP20010133A2 (en) 2002-02-28
BG65179B1 (bg) 2007-05-31
DK1147105T3 (da) 2004-06-01
CZ20011550A3 (cs) 2001-08-15
SK285582B6 (sk) 2007-04-05
CA2340734A1 (en) 2000-06-22
PL346767A1 (en) 2002-02-25
IL141515A (en) 2005-09-25
AU1790600A (en) 2000-07-03
ATE266027T1 (de) 2004-05-15
KR20010073129A (ko) 2001-07-31
UA70340C2 (en) 2004-10-15
NO20012310L (no) 2001-05-10
NO317649B1 (no) 2004-11-29
EP1147105A1 (en) 2001-10-24
NO20012310D0 (no) 2001-05-10
HUP9802897A2 (hu) 2000-11-28
EP1147105B1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
JP5620340B2 (ja) 光学活性ピリジル−4h−1,2,4−オキサジアジン誘導体およびその血管疾患の治療における使用
JP4316794B2 (ja) イソキノリン誘導体及び医薬
JP2011201916A5 (cg-RX-API-DMAC7.html)
BR112012007828B1 (pt) compostos inibidores da xantina oxidase, processo para preparar os compostos, e, composição farmacêutica para a inibição da xantina oxidase
CA3066423A1 (en) Compounds for modulating s1p1 activity and methods of using the same
WO1997028130A1 (en) Isoquinoline derivatives and drugs
JPWO1999020620A1 (ja) イソキノリン誘導体及び医薬
TWI359016B (en) Heterocyclylacetic acids as inhibitors of tafia
HK1223357A1 (zh) 作為離子通道調節劑的稠合雜環化合物
TW200914438A (en) 3-disubstituted indol-2-one derivatives, preparation thereof and therapeutic application thereof
JP4261639B2 (ja) フェニルイミダゾール系抗高脂血症薬
JP4662979B2 (ja) 新規なβ−アゴニスト、その製造方法及びその薬物としての使用
WO2003106446A1 (en) Non-peptide gnrh agents, pharmaceutical compositions and methods for their use
CN102603755B (zh) 一类具有协同氟康唑抗耐药真菌作用的化合物
EP0718290B1 (en) Carboxyalkyl heterocyclic derivatives
JPS6124579A (ja) 置換されたフエノキシアルキルアミノプロパノール
JP2003529600A (ja) 新規なベンゾスルタムオキサゾリジノン抗菌剤
JPH02149571A (ja) 強心アルカノイル及びアロイルオキサゾロン類
CN108774220A (zh) 用于治疗心肌缺血的化合物及其应用
JPH0770083A (ja) イミダゾール誘導体を有効成分とする血圧降下剤
FR2695388A1 (fr) Dérivés de 1,3,4-benzotriazépin-5(4H)-one et procédé pour leur préparation.
JPS63258418A (ja) イミダゾール−2−チオン類によって再潅流傷害を低下させる組成物
BE892084A (fr) Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments
JPWO2002048096A1 (ja) ヒドラゾン誘導体およびその医薬用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: ORPHAZYME A/S

Free format text: FORMER NAME(S): ORPHAZYME APS

MK14 Patent ceased section 143(a) (annual fees not paid) or expired